CoChat

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Open access
Zhang, Jie, Xian, Tong-Zhang, Teng, Yu, Wang, Xiuzhi, Wu, Ming-Xiao, Li, Chen, Wang, Weihao, Man, Fuli, Zhang, Xianbo, Wang, Xiaoxia, Guo, Li-Xin · 2022 · International Journal of Clinical Practice

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background. Exenatide is a glucagon‐like peptide‐1 receptor agonist that can reduce body weight. This study aimed to determine the efficacy of exenatide on body mass index (BMI) reduction in patients with type 2 diabetes mellitus (T2DM) with differing baseline body weight, blood glucose, and atherosclerotic status and to determine if there is a correlation between BMI reduction and cardiometabolic indices in these patients. Methods. This retrospective cohort study used data from our randomized controlled trial. A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included. The primary endpoint was a change in the BMI from the baseline to week 52. The secondary endpoint was a correlation between BMI reduction and cardiometabolic indices. Findings. The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) ≥ 9% significantly decreased −1.42 ± 1.48 kg/m 2(P = 0.015) and −0.87 ± 0.93 kg/m 2(P = 0.003), respectively, at the baseline after 52 weeks of treatment. There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group. The decrease in BMI was positively correlated with changes in blood glucose, high‐sensitivity C‐reactive protein (hsCRP), and systolic blood pressure (SBP). Conclusion. BMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2022/7128859

Cites

Statistics

Figures

Figure 1 BMI reduction in T2DM patients with differing baseline characteristics after exenatide treatment for 52 weeks (∗P < 0.05vs. baseline).
Figure 1 BMI reduction in T2DM patients with differing baseline characteristics after exenatide treatment for 52 weeks (∗P < 0.05vs. baseline).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 36 · Cited by 2

Metadata

Authors
Zhang, J., Xian, T.-Z., Teng, Y., Wang, X., Wu, M.-X., Li, C., Wang, W., Man, F., Zhang, X., Wang, X., & Guo, L.-X.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Wang, Xiaoxia
Venue
International Journal of Clinical Practice
Publisher
Wiley
Published
2022-01
Volume
2022
Issue
1
Pages
7128859-7128859
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
OpenAlex
W4304118555
Cited by
2
References
36
Citations by year
2026: 1 · 2024: 1
FWCI
0.19
Type
journal article
Language
en
Open access
Locations
  • International Journal of Clinical Practice (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
exenatide, type 2 diabetes, body mass index reduction, weight loss, GLP-1 receptor agonists, metformin combination therapy, HbA1c, atherosclerosis, high-sensitivity C-reactive protein, systolic blood pressure, obesity
MeSH terms
Exenatide, Blood Glucose, Body Weight, C-Reactive Protein, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Retrospective Studies, Venoms, Weight Loss, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1155/2022/7128859
The paper
Zhang, J., Xian, T.-Z., Teng, Y., Wang, X., Wu, M.-X., Li, C., Wang, W., Man, F., Zhang, X., Wang, X., & Guo, L.-X. (2022). Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus. International Journal of Clinical Practice. https://doi.org/10.1155/2022/7128859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.